Evaluating the Efficacy and Safety of Multi-Dose Pridopidine in Huntington Disease: The PRIDE-HD Study

被引：0
|
作者：
Papapetropoulos, Spyros [1 ]
Reilmann, Ralf [2 ]
Kieburtz, Karl [3 ]
McGarry, Andrew [4 ]
Eyal, Eli [5 ]
Grachev, Igor [1 ]
Borowsky, Beth [1 ]
Landwehrmeyer, Bernhard [6 ]
Hayden, Michael [1 ]
机构：
[1] Teva Pharmaceut Ind, Frazer, PA USA
[2] George Huntington Inst, Munster, Germany
[3] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA
[4] Cooper Univ Hlth Care, Movement Disorders Ctr, Camden, NJ USA
[5] Teva Pharmaceut Ind, Petah Tiqwa, Israel
[6] Univ Ulm, Dept Neurol, Ulm, Germany
来源：
NEUROTHERAPEUTICS | 2017年 / 14卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1
引用
收藏
页码：232 / 233
页数：2
相关论文
共 50 条
  • [1] Efficacy, Safety, and Tolerability of Pridopidine in Huntington's disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
    Reilmann, R.
    McGarry, A.
    Landwehrmeyer, G.
    Kieburtz, K.
    Grachev, I.
    Eyal, E.
    Savola, J.
    Borowsky, B.
    Papapetropoulos, S.
    Hayden, M.
    MOVEMENT DISORDERS, 2017, 32
  • [2] Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
    Reilmann, Ralf
    McGarry, Andrew
    Grachev, Igor D.
    Savola, Juha-Matti
    Borowsky, Beth
    Eyal, Eli
    Gross, Nicholas
    Langbehn, Douglas
    Schubert, Robin
    Wickenberg, Anna Teige
    Papapetropoulos, Spyros
    Hayden, Michael
    Squitieri, Ferdinando
    Kieburtz, Karl
    Landwehrmeyer, G. Bernhard
    Agarwal, Pinky
    Anderson, Karen E.
    Aziz, Nasir A.
    Azulay, Jean-Phillippe
    Bachoud-Levi, Anne C.
    Barker, Roger
    Bebak, Agnieszka
    Beuth, Markus
    Biglan, Kevin
    Blin, Stephanie
    Bohlen, Stefan
    Bonelli, Raphael
    Caldwell, Sue
    Calvas, Fabienne
    Carlos, Jonielyn
    Castagliuolo, Simona
    Chong, Terrence
    Chua, Phyllis
    Coleman, Allison
    Corey-Bloom, Jody
    Cousins, Rebecca
    Craufurd, David
    Davison, Jill
    Decorte, Eric
    De Michele, Giuseppe
    Dornhege, Laura
    Feigin, Andrew
    Gallehawk, Stephanie
    Gauteul, Pascale
    Gonzales, Carey
    Griffith, Jane
    Gustov, Alexander
    Guttman, Mark
    Heim, Beatrix
    Heller, Hope
    LANCET NEUROLOGY, 2019, 18 (02): : 165 - 176
  • [3] Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD
    Kieburtz, Karl
    Landwehrmeyer, G. Bernhard
    Reilmann, Ralf
    Savola, Juha
    Eyal, Eli
    Grachev, Igor
    Borowsky, Beth
    McGarry, Andrew
    Papapetropoulos, Spyros
    Hayden, Michael
    NEUROLOGY, 2017, 88
  • [4] Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
    McGarry, Andrew
    Leinonen, Mika
    Kieburtz, Karl
    Geva, Michal
    Olanow, C. Warren
    Hayden, Michael
    JOURNAL OF HUNTINGTONS DISEASE, 2020, 9 (04) : 371 - 380
  • [5] The PROOF-HD Study: Pridopidine's Outcome on Function in Huntington's Disease
    Reilmann, Ralf
    Feigin, Andrew S.
    Geva, Michal
    McGarry, Andrew
    Cohen, Yael
    Gershoni-Emek, Noga
    Mehra, Munish
    Olanow, C. Warren
    Kieburtz, Karl
    Hayden, Michael R.
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 32 - 33
  • [6] Design of the dose-range finding (DRF), randomized, doubleblind, placebo-controlled study, evaluating the safety and efficacy of pridopidine for symptomatic treatment in patients with Huntington's disease
    Landwehrmeyer, G. B.
    Reilmann, R.
    Kieburtz, K.
    Eyal, E.
    Wickenberg, A.
    Bassan, M.
    MOVEMENT DISORDERS, 2014, 29 : S211 - S211
  • [7] Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
    Suhr, Ole B.
    Coelho, Teresa
    Buades, Juan
    Pouget, Jean
    Conceicao, Isabel
    Berk, John
    Schmidt, Hartmut
    Waddington-Cruz, Marcia
    Campistol, Josep M.
    Bettencourt, Brian R.
    Vaishnaw, Akshay
    Gollob, Jared
    Adams, David
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [8] Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
    Ole B Suhr
    Teresa Coelho
    Juan Buades
    Jean Pouget
    Isabel Conceicao
    John Berk
    Hartmut Schmidt
    Márcia Waddington-Cruz
    Josep M. Campistol
    Brian R. Bettencourt
    Akshay Vaishnaw
    Jared Gollob
    David Adams
    Orphanet Journal of Rare Diseases, 10
  • [9] Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease
    Lundin, A.
    Dietrichs, E.
    Haghighi, S.
    Goeller, M.-L.
    Heiberg, A.
    Loutfi, G.
    Widner, H.
    Wiktorin, K.
    Wiklund, L.
    Svenningsson, A.
    Sonesson, C.
    Waters, N.
    Waters, S.
    Tedroff, J.
    MOVEMENT DISORDERS, 2010, 25 (07) : S274 - S274
  • [10] Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
    Lundin, Anders
    Dietrichs, Espen
    Haghighi, Sara
    Goller, Marine-Louise
    Heiberg, Arvid
    Loutfi, Ghada
    Widner, Hakan
    Wiktorin, Klas
    Wiklund, Leif
    Svenningsson, Anders
    Sonesson, Clas
    Waters, Nicholas
    Waters, Susanna
    Tedroff, Joakim
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (05) : 260 - 264
12345